Loading provider…
Loading provider…
Hematology & Oncology Physician in Boston, MA
NPI: 1396706503Primary Practice Location
BRIGHAM AND WOMEN'S HOSPITAL
75 Francis St, Boston, MA
Primary Employer
Binney Medical Associates
brighamandwomens.org
HQ Phone
Get MBBS DPHIL John's Phone Numberphone_androidMobile
Get MBBS DPHIL John's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMA State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 56 | 143 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 30 | 76 |
| 3 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 28 | 87 |
| 4 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 25 | 102 |
Authors: Vincent Ho, Robert Soiffer, Joseph Antin, Zhonghui Luo, Mahasweta Gooptu, Amy Han, Philippe Armand
Journal: Transplant Cell Ther
Publication Date: 2021-02-14
The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation.
Authors: Vincent Ho, Robert Soiffer, Joseph Antin, Karim Abou-Nassar, Philippe Armand
Publication Date: 2011-06-02
Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.
Authors: Vincent Ho, Robert Soiffer, Jerome Ritz, Joseph Antin, Philippe Armand
Publication Date: 2014-10-11
Lead Sponsor: Dana-Farber Cancer Institute
Collaborators: Prometheus Laboratories
Intervention / Treatment: DRUG: Interleukin-2, PROCEDURE: Extracorporeal Photopheresis (ECP)
Lead Sponsor: Dana-Farber Cancer Institute
Collaborators: National Cancer Institute (NCI), Miltenyi Biomedicine GmbH, Iovance Biotherapeutics, Inc.
Intervention / Treatment: DRUG: Interleukin-2, OTHER: Treg-enriched infusion
Lead Sponsor: Dana-Farber Cancer Institute
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Ipilimumab, BIOLOGICAL: CD25hi Treg depleted DLI